Previous 10 | Next 10 |
- First Anti-TL1A trial in Crohn’s Disease - - APOLLO-CD Phase 2a along with ARTEMIS-UC Phase 2 topline results expected in fourth quarter 2022 - - Final Phase 1a results for PRA023 in normal healthy volunteers expected in fourth quarter 2021- SAN DIEGO, Aug...
solarseven/iStock via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...
Prometheus Biosciences (RXDX) announces the initiation of the Phase 2 ARTEMIS-UC trial evaluating PRA023 for moderate-to-severe ulcerative colitis ((UC)).The company highlighted that the Phase 2a initiation in Crohn’s Disease ((CD)) on track for the third-quarter of 2021.Prom...
-First precision approach to IBD by utilizing a companion diagnostic to identify patients- -Phase 2a initiation in Crohn’s Disease on track for 3 rd Quarter 2021- - Further details to be provided at R&D Day on July 28 th - SAN DIE...
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the trea...
Mir Basar Suhaib/iStock via Getty Images Recently IPO’ed biotech firms Prometheus Biosciences ([[RXDX]] -21.5%) and Recursion Pharmaceuticals ([[RXRX]] -19.2%) are on course to record their biggest one-day losses since their public debut in March and April, respectively. As demons...
-Prometheus receives $10 million payment triggered by selection of clinical candidate for PR600- -IND for PR600 expected in 3Q 2022- SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a ...
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treat...
Following a gain of ~21.8% yesterday, Prometheus Biosciences ([[RXDX]] +1.8%) is continuing the momentum today in apparent reaction to the appointment of industry veteran Fred Hassan to its board of directors.Mr. Hassan was a former chairman of Bausch & Lomb from 2010 until the ...
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treat...
News, Short Squeeze, Breakout and More Instantly...
Prometheus Biosciences Inc. Company Name:
RXDX Stock Symbol:
NASDAQ Market:
Prometheus Biosciences Inc. Website:
NEW YORK, NY / ACCESSWIRE / May 25, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Prometheus Biosciences, Inc. (NASDAQ:RXDX...
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated disease...